Atypical antipsychotics in the treatment of schizophrenia

BMJ

Volumn 322, Issue 7291, 2001, Pages 924-

  Prior, Cliff ^a   Clements, Judi ^b   Rowett, Michelle ^c   Taylor, David ^d   Rowsell, Rhiannon ^g   Link, Christopher ^e   Donoghue, John ^f   Lee, Sing ^h   Anderson, Ian ⁱ   Duggins, Richard ^j   Rhinds, David ^j   Hall, William ^j   Kerwin, Robert ^k   Adams, Clive ^l   Duggan, Lorna ^m   Geddes, John ^l   Harrison, Paul ^l   Freemantle, Nick ⁿ   Bebbington, Paul ^o  

^a National Schizophrenia Fellowship   (United Kingdom)

^b Mind   (United Kingdom)

^c Kingston upon Thames   (United Kingdom)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e ASTRAZENECA   (United Kingdom)

^f University of Manchester ^*  (United Kingdom)

^g Duncan MacMillan House ^*

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m ST ANDREW S HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^o ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007662086     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.322.7291.924/a     Document Type: Letter

References (31)

1. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
2. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
3. Taylor D. Low dose typical antipsychotics—a brief evaluation. Psychiatr Bull 2000; 24: 465–468.
4. Taylor D, Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. J Psychopharmacol 2000; 4: 409–418.
5. Taylor D, Mace S, Mir S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psych Clin Pract 2000; 4: 41–46.
6. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
7. Kerwin R, Taylor D. New antipsychotics: a review of their current status and clinical potential. CNS Drugs 1996; 6: 71–82.
8. Hamner MB, Arana GW. Hyperprolactinaemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998; 10: 209–222
9. Peuskens J, Link CJ. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–273.
10. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 1997; 42: 233–246.
11. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
12. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
13. Lawrenson RA, Tyrer F, Newson RB, Farmer RD. The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149–157.
14. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360–1361. (2 December.)
15. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
16. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360–1361. (2 December.)
17. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis BMJ 2000; 321: 1371–1376. (2 December.)
18. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360–1361. (2 December.)
19. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment resistant schizophrenic: a double blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
20. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155: 914–920.
21. Remington G, Kapur S, Zipursky RB. The pharmacotherapy of first episode schizophrenia. Br J Psychiatry 1998; 172(suppl):66–70.
22. Smith R. The failings of NICE. BMJ 2000; 321: 1363–1364. (2 December.)
23. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–1376. (2 December.)
24. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360–1361. (2 December.)
25. NHS Centre for Reviews and Dissemination. Drug treatments for schizophrenia. Effective Health Care 1999; 5: 1–12. (www.york.ac.uk/inst/crd/ehc56.htm.)
26. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S. Olanzapine for schizophrenia. In: Cochrane library. Issue 4. Oxford: Update Software, 2000. (2 December.)
27. Kapur S, Remington G. Atypical antipsychotics. BMJ 2000; 321: 1360–1361. (2 December.)
28. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–796.
29. Marder SR. An approach to treatment resistance in schizophrenia. Br J Psychiatry 1999; 37(suppl):19–22.
30. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995; 14: 2685–2699.
31. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994; 309: 1351–1355.